Results 121 to 130 of about 19,221 (177)

Who Wins the Battle Against Obesity? A Network Meta‐Analysis Comparing Tirzepatide and Semaglutide

Journal of Diabetes, Volume 18, Issue 2, February 2026.
Network meta‐analysis comparing the effects of tirzepatide, semaglutide, and placebo on body weight reduction and glycemic outcomes in adults with overweight or obesity. ABSTRACT Introduction Pharmacological therapies are recommended for individuals with obesity.
Julia C. Bernardi, Deivyd V. S. Cavalcante, Ramon Huntermann, Maria E. Molinari, Luana Z. Zanon, Jacinthe Khater, Victor A. Gomez, Caroline O. Fischer‐Bacca   +7 more
wiley   +1 more source

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

The value and impact of weight reduction from the perspective of people with type 2 diabetes in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1116-1125, February 2026.
Abstract Aims To understand the importance and potential impacts of reaching a lower weight or body mass index (BMI) from the perspectives of people with type 2 diabetes (T2D) across BMI levels. Materials and methods A cross‐sectional survey, informed by qualitative interviews, was administered to a sample representative of the US T2D population by BMI.
Melissa M. Ross, Sarah Mulnick, Kristina S. Boye, Ashley Samuelson, Vivian Thuyanh Thieu, Christine Longuet, Jennifer Glass, Meredith M. Hoog   +7 more
wiley   +1 more source

A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1160-1167, February 2026.
Abstract Aims Targeting the glucose dependent insulinotropic polypeptide receptor (GIPR) is of growing interest for treating type 2 diabetes and obesity, though the optimal approach remains unclear. Both GIPR agonism and antagonism, respectively, incorporated into drugs like tirzepatide and maridebart cafraglutide, have paradoxically both shown ...
Iona Davies, Alexandra Turland, Hanh Duyen Tran, Carissa Wong, Olivier Cahn, Cecilia Dunsterville, Yichang Sun, Yilin Xiao, Kevin G. Murphy, Stephen R. Bloom, Ben Jones, Tricia M. M. Tan   +11 more
wiley   +1 more source

Tirzepatide - role in obesity, health and physical wellness. Information overview

Quality in Sport
Nowadays there is an increasing number of people with overweight and obesity all around the world. Unhealthy food, sweets and fast foods are available everywhere, that causes self-perpetuating problem. Food restriction is an obvious treatment, but it is
Anna Hanslik, Magdalena Mendak, Agata Białek, Agnieszka Walczak, Adrian Hovagimyan, Monika Olszanecka, Tomasz Olszanecki   +6 more
doaj   +1 more source

Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1191-1200, February 2026.
Abstract Aim This study aimed to investigate the efficacy and safety of bi‐weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods This multicenter, open‐label, randomized controlled study assigned participants in a 1:1 ratio to either the ...
Congqing Pan, Hongwei Jiang, Yi Feng, Suijun Wang, Jin Zhang, Zhongjing Wang, Yusen Zhou, Fangqiong Li, Zhanhui Zhang, Yaming Li, Liming Chen   +10 more
wiley   +1 more source

The novel adiponectin-resistin (AR) and insulin resistance (IR~AR~) indexes [PDF]

, 2010
Serum hypoadiponectinemia and hyperrestinemia independently links insulin resistance to type 2 diabetes (T2DM) and metabolic syndrome (MS). Thus, the aim of this study was propose a novel adiponectin-resistin (AR) index by unifying the effect of ...
Cia-Hin Lau, Sekaran Muniandy
core   +1 more source

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT‐J trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1278-1287, February 2026.
Abstract Aims This analysis aimed to assess the influence of selected baseline factors on tirzepatide treatment response in Japanese patients with obesity disease. Materials and Methods This was a prespecified subgroup analysis of the SURMOUNT‐J trial.
Koutaro Yokote, Yasushi Fukushima, Tomotaka Shingaki, Tomonori Oura, Wataru Ogawa   +4 more
wiley   +1 more source

Heart matters: How glucose‐ and lipid‐modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 878-894, February 2026.
Abstract Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and the visceral pericardium, exerting direct paracrine and vasocrine effects on the heart and coronary vessels. Under physiological conditions, EAT supports myocardial energy metabolism and thermoregulation through fatty acid supply and
Elisabeth Heuboeck, Charnkamal Singh Bhogal, Markus Mandl   +2 more
wiley   +1 more source